Janux Therapeutics Doses First Patient in JANX014 Study
SAN DIEGO, USA, April 16, 2026 Janux Therapeutics, Inc. has announced a key clinical milestone with the first participant...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SAN DIEGO, USA, April 16, 2026 Janux Therapeutics, Inc. has announced a key clinical milestone with the first participant...
SAN DIEGO, January 22, 2026 — Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers...
